$ABXXF

Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals

Abaxx Technologies said it is not under investigation by any regulator and has contacted CIRO to request an investigation into potentially manipulative or deceptive trading in its common shares, according to the company. Abaxx also retained Paul, Weiss to investigate alleged wrongdoing by Viceroy. The company reported C$97 million+ in cash as of June 2026 and June ADV of 16,846 contracts.

Original reporting
Published Jun 22, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 1:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals — source image
Decision brief

The 30-second read

$ABXXFBullishLow
01

Why it matters

The key tradable element is whether regulators act: Abaxx requests CIRO investigation into potentially manipulative trading and claims neither it nor subsidiaries are under investigation, alongside liquidity and market-surveillance assertions.

02

Market read

Provides defensive disclosures (no investigation claim, cash/burn/runway, and wash-trading controls) but no confirmed regulatory outcome.

03

What to watch

Investors may discount PR-heavy rebuttals without independent verification; watch for any CIRO/MAS responses, formal complaints, or subsequent filings that confirm or refute the allegations.

Relevance 4/10Novelty 4/10Timing: today/this week as a response to Viceroy’s ongoing campaign

Background

Abaxx Technologies is responding to an ongoing misinformation campaign by Viceroy Research Group and is seeking regulatory and legal review.

Company-level read

Ticker impact

$ABXXFBullishMedium confidence
Context

Abaxx says it is not under investigation, urges CIRO to probe Viceroy’s alleged manipulation, and reports C$97M cash plus 7-quarter runway.

Expected impact

Near-term: modest support if investors view the cash/runway and “no investigation” claim as credible; downside risk remains if Viceroy’s allegations gain traction or regulators open inquiries.

Evidence & confidence

The article provides specific, decision-relevant assertions (no regulator investigation, cash balance, burn rate, and market surveillance) but does not disclose any regulator action or new legal outcome.

Market effects

Could influence sentiment toward commodity exchange/market-infrastructure operators if the dispute escalates into regulatory scrutiny.

Primarily affects Canadian/SG market-structure participants tied to Abaxx Exchange and clearing.

Limited unless regulators broaden the case to other exchange operators or market-manipulation practices.

Counterpoint

“No investigation” and cash/runway statements may not neutralize skepticism if regulators later confirm inquiries or if Viceroy’s claims are substantiated.

Key entities

  • Abaxx Technologies Inc.

    Financial software and market infrastructure company; subject of the rebuttal and regulatory outreach.

  • Viceroy Research Group

    Research group Abaxx accuses of a short-and-distort campaign and alleged manipulative trading.

  • CIRO

    Canadian Investment Regulatory Organization; Abaxx urges it to investigate trading activity.

  • Monetary Authority of Singapore (MAS)

    Singapore regulator; Abaxx says it has reached out regarding Viceroy’s allegations.

  • Paul, Weiss, Rifkind, Wharton & Garrison LLP

    U.S. law firm retained to investigate wrongdoing related to Viceroy’s campaign and trading.

Related articles

$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

$VYLRMed

Vylor Inc. (VYLR): 15 states and one sovereign commenced litigation in the United States District Court for the Southern District of Indiana challenging the separation of…

Vylor Inc. (VYLR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 1, 2026, 15 states and one sovereign commenced litigation in the United States District Court for the Southern District of Indiana (the “District Court”) challenging the separation of Corteva, Inc. (“Corteva”) and Vylor Inc. (the “Company” or “V

$TSLAMed

Tesla Rebrands Full Self-Driving In Europe After Regulators Called Name Misleading

Tesla has rebranded its driver-assistance system from 'Full Self-Driving' to 'Tesla Assisted Driving' in Europe. The change follows regulatory concerns from Germany's transport ministry, which deemed the old name misleading. The system's features have also been modified to comply with EU rules. A broader European approval vote is set for December, with Germany pushing for stricter speed limits. France has not yet approved the system, citing safety concerns.

$CGCMed

Canopy Growth’s Ontario facility receives EU GMP certification

Canopy Growth (TSX:WEED, NASDAQ:CGC) announced its Smiths Falls, Ontario facility received EU GMP certification, covering softgel and cannabis flower production. The company claims it's the only Canadian facility with this combined scope certification. This supports medical cannabis supply to Europe, aligning with its expansion strategy in Germany, Poland, and the UK. The certification follows a similar one for its Kincardine facility.